MoneyWorks4Me

Parmax Pharma informs about disclosure

17 Aug 2026 Evaluate
Parmax Pharma has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Alkesh Mahasukhlal Gopani & Others.

The above information is a part of company’s filings submitted to BSE.  

Parmax Pharma Share Price

122.50 2.40 (2.00%)
18-Aug-2026 13:16 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1878.00
Dr. Reddys Labs. 1186.50
Cipla 1433.90
Lupin 2225.90
Zydus Lifesciences 1123.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: